Pharmaceuticals

Global Rituximab Biosimilars Market Size, Forecasts, And Opportunities

November 26, 2021 by The Business Research Company

Learn about the global rituximab biosimilars market through The Business Research Company, which provides information on rituximab biosimilars market size, rituximab biosimilars market drivers and restraints, rituximab biosimilars market players, the COVID-19 impact on the rituximab biosimilars market, and more.

Our annual holiday sale is here! Get your discounted market research reports today.

The global rituximab biosimilars market is expected to grow from $1.75 billion in 2020 to $1.9 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The rituximab biosimilars market is expected to reach $3.02 billion in 2025 at a CAGR of 12%.

The rising prevalence of non-Hodgkin’s lymphoma (NHL) is expected to drive innovation in rituximab biosimilars manufacturing, thus driving the market during the forecast period.

Request A Sample For The Global Rituximab Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smph

The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA).

Global rituximab biosimilars market segments include:

By Application: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukaemia, Rheumatoid Arthritis, Others

By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels

By Route Of Administration: Subcutaneous, Intravenous, Molecular Type

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

The companies operating in the biosimilars are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market.

TBRC’s rituximab biosimilars market report covers:

Major Market Players: Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)

The Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030 is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market overviews, analyzes and forecasts market size, share, rituximab biosimilars market players, rituximab biosimilars market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s rituximab biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here is a list of similar reports from The Business Research Company:

Biosimilars Global Market Report 2021

Filgrastim Biosimilars Market

Interested to know more about The Business Research Company?

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our Blog: https://blog.tbrc.info/

Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model